title: Foscarnet decreases HIV-1 plasma load.
abstract: OBJECTIVE
  To evaluate the effect of foscarnet on HIV-1 replication in vivo.
  
  
  METHODS
  Seventeen AIDS patients with cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV) infection, Kaposi's sarcoma (KS), or a combination of these were treated with foscarnet. HIV RNA quantification (bDNA 2.0, Chiron, Emeryville, CA, U.S.A.), CMV pp65 antigenemia (Argene Biosoft, Varilhes, France), and CMV viremia were determined before and during therapy.
  
  
  RESULTS
  Four patients had CMV retinitis (1 with KS), 2 patients had CMV pneumonia (1 with KS), 1 patient had CMV cholecystitis, 2 patients had VZV infection (1 with KS), 1 patient had HSV-2 infection, and 7 patients had KS alone. The decrease in HIV-1 load was -0.73 +/- 0.39 log copies/ml (p = 2.10(-6)) after 3 days of treatment and -1.15 +/- 0.49 log copies/ml (p < 10(-7)) after 10 days of treatment, compared with day 0. Furthermore, reduction of HIV-1 plasma load during foscarnet therapy did not depend on the presence or absence of CMV disease or on a positive pp65 antigenemia at day 0.
  
  
  CONCLUSIONS
  We observed decreased HIV-1 plasma load in all patients treated with foscarnet, regardless of presence or absence of clinical or biologic CMV infection. This decrease supports the proposition that foscarnet anti-HIV-1 activity may be of clinical importance.
authors.affiliation: Laboratoire de Virologie, CHU de Bordeaux, France.
authors.forename: I
authors.initials: I
authors.lastname: Devianne-Garrigue
authors.forename: I
authors.initials: I
authors.lastname: Pellegrin
authors.forename: R
authors.initials: R
authors.lastname: Denisi
authors.forename: M
authors.initials: M
authors.lastname: Dupon
authors.forename: J M
authors.initials: JM
authors.lastname: Ragnaud
authors.forename: P
authors.initials: P
authors.lastname: Barbeau
authors.forename: D
authors.initials: D
authors.lastname: Breilh
authors.forename: B
authors.initials: B
authors.lastname: Leng
authors.forename: H J
authors.initials: HJ
authors.lastname: Fleury
authors.forename: J L
authors.initials: JL
authors.lastname: Pellegrin
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000150:complications; D005260:Female; D017245:Foscarnet / Q000494:pharmacology / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D006561:Herpes Simplex / Q000150:complications; D006562:Herpes Zoster / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D012514:Sarcoma, Kaposi / Q000150:complications; D019562:Viral Load; D014766:Viremia / Q000150:complications / Q000188:drug therapy / Q000821:virology; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D017245:Foscarnet